• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

    11/13/24 9:00:21 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADPT alert in real time by email
    SC 13G/A 1 p24-3149sc13ga.htm ADAPTIVE BIOTECHNOLOGIES CORPORATION
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    Adaptive Biotechnologies Corporation

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    00650F109

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    o Rule 13d-1(b)
    o Rule 13d-1(c)
    ý Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 00650F10913G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Matrix Capital Management Company LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    650,000

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    650,000

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    650,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.44%

    12

    TYPE OF REPORTING PERSON

    IA, PN

             

     

     

    CUSIP No. 00650F10913G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    David E. Goel

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    650,000

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    650,000

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    650,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.44%%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

    CUSIP No. 00650F10913G/APage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Adaptive Biotechnologies Corporation, a Washington corporation (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 1165 Eastlake Avenue East, Seattle, Washington 98109.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:

     

      (i) Matrix Capital Management Company LP (the "Investment Manager"), a Delaware limited partnership, and the investment advisor to Matrix Capital Management Master Fund, LP (the "Matrix Fund"), with respect to the shares of Common Stock (as defined in Item 2(d)) directly held by the Matrix Fund; and
       
      (ii) Mr. David E. Goel ("Mr. Goel"), who serves as the Managing General Partner of the Investment Manager, with respect to the shares of Common Stock held by the Matrix Funds.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is c/o Matrix Capital Management Company LP, Bay Colony Corporate Center, 1000 Winter Street, Suite 4500, Waltham, MA 02451.

     

    Item 2(c). CITIZENSHIP:
       
      The Investment Manager is a Delaware limited partnership.  Mr. Goel is a United Stated citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      00650F109

     

     

    CUSIP No. 00650F10913G/APage 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨

    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

      (e) ¨ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: ___________________________.

     

    Item 4. OWNERSHIP:
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentages used herein are calculated based upon 147,472,201 shares of Common Stock outstanding as of July 29, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 1, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ý

     

     

    CUSIP No. 00650F10913G/APage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:
       
      Not applicable.

     

     

     

    CUSIP No. 00650F10913G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 13, 2024

     

    MATRIX CAPITAL MANAGEMENT COMPANY LP  
       
       
    By: /s/ David E. Goel  
    Name:  David E. Goel  
    Title:    Managing General Partner  
       
       
    /s/ David E. Goel  
    DAVID E. GOEL  
         

     

     

    Get the next $ADPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADPT

    DatePrice TargetRatingAnalyst
    3/21/2025$9.00Neutral → Buy
    Goldman
    7/5/2023$15.00Overweight
    JP Morgan
    1/5/2023$15.00Sector Outperform
    Scotiabank
    12/21/2022$7.50 → $14.00Neutral → Overweight
    Piper Sandler
    8/25/2022$8.00Underperform
    Credit Suisse
    6/3/2022$7.50Neutral
    Piper Sandler
    2/16/2022$40.00 → $32.00Buy
    BofA Securities
    2/16/2022$75.00 → $50.00Overweight
    JP Morgan
    More analyst ratings

    $ADPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

      For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

      3/5/21 10:37:33 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ADPT
    SEC Filings

    See more

    $ADPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ADPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ADPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adaptive Biotechnologies upgraded by Goldman with a new price target

      Goldman upgraded Adaptive Biotechnologies from Neutral to Buy and set a new price target of $9.00

      3/21/25 8:00:43 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on Adaptive Biotechnologies with a new price target

      JP Morgan resumed coverage of Adaptive Biotechnologies with a rating of Overweight and set a new price target of $15.00

      7/5/23 7:14:22 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Adaptive Biotechnologies with a new price target

      Scotiabank initiated coverage of Adaptive Biotechnologies with a rating of Sector Outperform and set a new price target of $15.00

      1/5/23 7:29:02 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Adaptive Biotechnologies Corporation

      10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)

      5/1/25 4:30:23 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)

      5/1/25 4:15:13 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Adaptive Biotechnologies Corporation

      DEFA14A - Adaptive Biotechnologies Corp (0001478320) (Filer)

      4/29/25 4:07:22 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

      SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/13/24 4:30:24 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

      SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/13/24 9:00:21 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

      SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/12/24 1:30:57 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Financial Officer Piskel Kyle sold $17,149 worth of shares (1,929 units at $8.89), decreasing direct ownership by 0.71% to 269,581 units (SEC Form 4)

      4/A - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/20/25 7:46:28 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Piskel Kyle was granted 7,815 shares and sold $17,149 worth of shares (1,929 units at $8.89), increasing direct ownership by 2% to 277,396 units (SEC Form 4)

      4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/19/25 7:59:39 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Robins Harlan S exercised 68,412 shares at a strike of $6.32 and sold $502,828 worth of shares (68,412 units at $7.35) (SEC Form 4)

      4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/5/25 5:27:53 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. "We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This performance highlights the scalability of our MRD business and the growing momentum behind it. As a resul

      5/1/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours

      4/10/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

      SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostic Services Program (MolDX), has expanded coverage of clonoSEQ® to include single time point testing to monitor for recurrence in patients with a history of mantle cell lymphoma (MCL). This expanded coverage is in addition to the existing Medicare episode payment structure for clonoS

      4/8/25 8:00:00 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Financials

    Live finance-specific insights

    See more
    • Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. "We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This performance highlights the scalability of our MRD business and the growing momentum behind it. As a resul

      5/1/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours

      4/10/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

      SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. "2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements in our Immune Medicine programs. Our MRD revenue grew by 42%, with a 35% increase in clonoSEQ test volume, and we nominated a lead autoimmune indication within our Immune Medicine business," said Chad

      2/11/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

      SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. "Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medic

      3/9/22 7:00:00 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

      SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health. "Adaptive has set the stage for commercial success with well-defined growth strategies and a solid pipeline for our current research and diagnostic products. Nit

      8/4/21 4:15:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care